A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections.
MT: Delivery Strategies
RNA vaccine
chikungunya virus
protection
replicon
taRNA
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
14 Jun 2022
14 Jun 2022
Historique:
received:
25
01
2022
accepted:
28
04
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
The arthritogenic alphavirus, chikungunya virus (CHIKV), is now present in almost 100 countries worldwide. Further spread is very likely, which raises public health concerns. CHIKV infections cause fever and arthralgia, which can be debilitating and last for years. Here, we describe a CHIKV vaccine candidate based on
Identifiants
pubmed: 35664702
doi: 10.1016/j.omtn.2022.04.036
pii: S2162-2531(22)00113-5
pmc: PMC9126847
doi:
Types de publication
Journal Article
Langues
eng
Pagination
743-754Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
U.S., T.B., and M.P. are inventors on patents and patent applications that cover parts of this article. U.S. is an employee at BioNTech Corporation (Mainz, Germany), a privately owned company developing therapeutic RNA. All others declare no competing interests.
Références
Gene Ther. 2021 Apr;28(3-4):117-129
pubmed: 33093657
Microbiol Rev. 1994 Sep;58(3):491-562
pubmed: 7968923
Cell Mol Life Sci. 2016 Oct;73(20):3897-916
pubmed: 27117550
Lancet Infect Dis. 2017 Apr;17(4):e107-e117
pubmed: 28159534
Mol Ther. 2018 Feb 7;26(2):446-455
pubmed: 29275847
Mol Ther Methods Clin Dev. 2020 Jun 18;18:402-414
pubmed: 32695842
Cell Rep. 2015 Dec 22;13(11):2553-2564
pubmed: 26686638
Emerg Infect Dis. 2006 Oct;12(10):1604-6
pubmed: 17176585
Nat Rev Drug Discov. 2021 Nov;20(11):817-838
pubmed: 34433919
J Virol. 2010 Aug;84(15):7543-57
pubmed: 20484502
Viruses. 2019 Jan 18;11(1):
pubmed: 30669393
Int J Infect Dis. 2017 May;58:69-76
pubmed: 28288924
J Infect Dis. 2020 Apr 27;221(10):1713-1723
pubmed: 31828322
J Virol. 1990 Apr;64(4):1726-33
pubmed: 2319651
Microorganisms. 2021 Apr 22;9(5):
pubmed: 33922370
Adv Drug Deliv Rev. 2021 Sep;176:113900
pubmed: 34324884
Cell Rep. 2021 Apr 6;35(1):108962
pubmed: 33826892
Mol Ther. 2019 Apr 10;27(4):824-836
pubmed: 30638957
Lancet. 2014 Dec 6;384(9959):2046-52
pubmed: 25132507
J Virol. 2011 May;85(10):4739-51
pubmed: 21389137
Nat Rev Drug Discov. 2014 Oct;13(10):759-80
pubmed: 25233993
J Virol Methods. 2014 Jun;201:7-12
pubmed: 24552952
Viruses. 2021 Jun 22;13(7):
pubmed: 34206519
J Virol. 2015 Nov 18;90(3):1687-92
pubmed: 26581991
Nat Med. 2010 Mar;16(3):334-8
pubmed: 20111039
Emerg Infect Dis. 2009 Mar;15(3):469-71
pubmed: 19239767
Front Immunol. 2020 Feb 21;11:287
pubmed: 32153590